Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000361694

Medchemexpress LLC BI-1622 | 2681392-19-6 | 99.0% | 508.53 | 5 MG
SDP

Catalog No. 5000361694
Encompass_Preferred

BI-1622 is an orally active, potent, and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM. It demonstrates over 25-fold selectivity for HER2 compared to EGFR. BI-1622 exhibits high antitumor efficacy in vivo in xenograft mouse tumor models using engineered H2170 and PC9 cells, and it possesses a favorable agent metabolism and pharmacokinetics profile.

  • Inhibits proliferation of HER2-dependent cell lines.
  • Induces a dose-dependent decrease in pHER2 and pERK levels.
  • Displays good permeability and no PgP-mediated efflux liability.
  • Shows good in vitro clearance in mouse liver microsomes and mouse hepatocytes.
  • Potently inhibited the proliferation of cancer cell lines dependent on amplified HER2 or an NRG-1 fusion.
  • Shows moderate clearance, a moderate volume of distribution, and good to moderate bioavailability up to 68%.
  • Inhibits tumor growth and oncogenic signaling.

Catalog No. 50-003-61694 Supplier Medchemexpress LLC Supplier No. HY1500235MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

BI-1622 is an orally active, potent, and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM. It demonstrates over 25-fold selectivity for HER2 compared to EGFR. BI-1622 exhibits high antitumor efficacy in vivo in xenograft mouse tumor models using engineered H2170 and PC9 cells, and it possesses a favorable agent metabolism and pharmacokinetics profile.

  • Inhibits proliferation of HER2-dependent cell lines.
  • Induces a dose-dependent decrease in pHER2 and pERK levels.
  • Displays good permeability and no PgP-mediated efflux liability.
  • Shows good in vitro clearance in mouse liver microsomes and mouse hepatocytes.
  • Potently inhibited the proliferation of cancer cell lines dependent on amplified HER2 or an NRG-1 fusion.
  • Shows moderate clearance, a moderate volume of distribution, and good to moderate bioavailability up to 68%.
  • Inhibits tumor growth and oncogenic signaling.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.